. 2014 Jul 30;8(4):1470–1476. doi: 10.3892/ol.2014.2396

Table III.

Univariate and multivariate analysis of survival in 270 patients with NSCLC.

	Univariate analysis (n=270)		Multivariate analysis (n=270)

Variable	Hazard ratio (95% CI)	P-value	Hazard ratio (95% CI)	P-value
NEK2-positive expression alone
Negative vs. positive	3.810 (2.064–7.036)	<0.0001^a	2.234 (1.104–4.523)	0.0250^a
Mcm7-positive expression alone
Negative vs. positive	3.117 (1.830–5.310)	<0.0001^a	1.920 (1.050–3.512)	0.0340^a
Ki67-positive expression alone
Negative vs. positive	3.060 (1.667–5.617)	<0.0001^a	2.179 (1.096–4.333)	0.0260^a
NEK2- and Mcm7-positive expression
NEK2- and Mcm7-negative vs. NEK2	6.360 (2.877–14.062)	<0.0001^a	5.218 (2.264–12.026)	<0.0001^a
Mcm7-positive vs. NEK2- and Mcm7-positive	2.786 (1.166–6.658)		2.402 (0.965–5.977)
NEK2- and Ki67-positive expression
NEK2- and Ki67-negative vs. NEK2	9.600 (3.221–28.610)	<0.0001^a	7.836 (2.494–24.625)	<0.0001^a
Ki67-positive vs. NEK2- and Ki67-positive	4.200 (1.328–13.280)		3.401 (1.026–11.276)
Age
<60 vs. ≥60	1.225 (0.754–1.991)	0.4120	1.136 (0.662–1.948)	0.6430
Gender
Female vs. male	1.023 (0.604–1.733)	0.9330	1.076 (0.596–1.943)	0.8070
Histological type
SCC vs. ADC	0.742 (0.454–1.211)	0.2330	0.663 (0.382–1.154)	0.1460
Tumor differentiation
Poor vs. well or moderate	1.211 (0.750–1.957)	0.4340	1.359 (0.793–2.328)	0.2640
T stage
I or II vs. III or IV	3.345 (1.657–6.754)	0.0010^a	2.228 (1.020–4.867)	0.0440^a
Lymph node status
Negative vs. N1-positive vs. N2-positive	2.236 (1.370–3.649)	0.0010^a	1.781 (1.038–3.054)	0.0360^a
M stage
M0 vs. M1	10×10⁹ (0.000)	0.9990	5×10⁸ (0.000)	0.9990

Significantly different.

NEK2, never in mitosis gene A (NIMA)-related kinase 2; mcm7, minichromosome maintenance complex component 7; NSCLC, non-small cell lung cancer; SSC, squamous cell carcinoma; ADC, adenocarcinoma; CI, confidence interval.